Combined in vivo MRI assessment of locus coeruleus and nucleus basalis of Meynert integrity in amnestic Alzheimer's disease, suspected-LATE and frontotemporal dementia.


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
03 May 2024
Historique:
received: 23 12 2023
accepted: 25 04 2024
medline: 4 5 2024
pubmed: 4 5 2024
entrez: 3 5 2024
Statut: epublish

Résumé

The locus coeruleus (LC) and the nucleus basalis of Meynert (NBM) are altered in early stages of Alzheimer's disease (AD). Little is known about LC and NBM alteration in limbic-predominant age-related TDP-43 encephalopathy (LATE) and frontotemporal dementia (FTD). The aim of the present study is to investigate in vivo LC and NBM integrity in patients with suspected-LATE, early-amnestic AD and FTD in comparison with controls. Seventy-two participants (23 early amnestic-AD patients, 17 suspected-LATE, 17 FTD patients, defined by a clinical-biological diagnosis reinforced by amyloid and tau PET imaging, and 15 controls) underwent neuropsychological assessment and 3T brain MRI. We analyzed the locus coeruleus signal intensity (LC-I) and the NBM volume as well as their relation with cognition and with medial temporal/cortical atrophy. We found significantly lower LC-I and NBM volume in amnestic-AD and suspected-LATE in comparison with controls. In FTD, we also observed lower NBM volume but a slightly less marked alteration of the LC-I, independently of the temporal or frontal phenotype. NBM volume was correlated with the global cognitive efficiency in AD patients. Strong correlations were found between NBM volume and that of medial temporal structures, particularly the amygdala in both AD and FTD patients. The alteration of LC and NBM in amnestic-AD, presumed-LATE and FTD suggests a common vulnerability of these structures to different proteinopathies. Targeting the noradrenergic and cholinergic systems could be effective therapeutic strategies in LATE and FTD.

Sections du résumé

BACKGROUND BACKGROUND
The locus coeruleus (LC) and the nucleus basalis of Meynert (NBM) are altered in early stages of Alzheimer's disease (AD). Little is known about LC and NBM alteration in limbic-predominant age-related TDP-43 encephalopathy (LATE) and frontotemporal dementia (FTD). The aim of the present study is to investigate in vivo LC and NBM integrity in patients with suspected-LATE, early-amnestic AD and FTD in comparison with controls.
METHODS METHODS
Seventy-two participants (23 early amnestic-AD patients, 17 suspected-LATE, 17 FTD patients, defined by a clinical-biological diagnosis reinforced by amyloid and tau PET imaging, and 15 controls) underwent neuropsychological assessment and 3T brain MRI. We analyzed the locus coeruleus signal intensity (LC-I) and the NBM volume as well as their relation with cognition and with medial temporal/cortical atrophy.
RESULTS RESULTS
We found significantly lower LC-I and NBM volume in amnestic-AD and suspected-LATE in comparison with controls. In FTD, we also observed lower NBM volume but a slightly less marked alteration of the LC-I, independently of the temporal or frontal phenotype. NBM volume was correlated with the global cognitive efficiency in AD patients. Strong correlations were found between NBM volume and that of medial temporal structures, particularly the amygdala in both AD and FTD patients.
CONCLUSIONS CONCLUSIONS
The alteration of LC and NBM in amnestic-AD, presumed-LATE and FTD suggests a common vulnerability of these structures to different proteinopathies. Targeting the noradrenergic and cholinergic systems could be effective therapeutic strategies in LATE and FTD.

Identifiants

pubmed: 38702802
doi: 10.1186/s13195-024-01466-z
pii: 10.1186/s13195-024-01466-z
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

97

Informations de copyright

© 2024. The Author(s).

Références

Ehrenberg AJ, Kelberman MA, Liu KY, et al. Priorities for research on neuromodulatory subcortical systems in Alzheimer’s disease: position paper from the NSS PIA of ISTAART. Alzheimers Dement. 2023;19(5):2182–96.
pubmed: 36642985 doi: 10.1002/alz.12937
Matchett BJ, Grinberg LT, Theofilas P, et al. The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer’s disease. Acta Neuropathol. 2021;141(5):631–50.
pubmed: 33427939 pmcid: 8043919 doi: 10.1007/s00401-020-02248-1
Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci. 2009;10:211–23.
pubmed: 19190638 doi: 10.1038/nrn2573
Šimić G, Babić Leko M, Wray S, et al. Monoaminergic neuropathology in Alzheimer’s disease. Prog Neurobiol. 2017;151:101–38.
pubmed: 27084356 doi: 10.1016/j.pneurobio.2016.04.001
Baxter MG, Chiba AA. Cognitive functions of the basal forebrain. Curr Opin Neurobiol. 1999;9:178–83.
pubmed: 10322180 doi: 10.1016/S0959-4388(99)80024-5
Sarter M, Bruno JP, Givens B. Attentional functions of cortical cholinergic inputs: what does it mean for learning and memory? Neurobiol Learn Mem. 2003;80:245–56.
pubmed: 14521867 doi: 10.1016/S1074-7427(03)00070-4
Grudzien A, Shaw P, Weintraub S, et al. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer’s disease. Neurobiol Aging. 2007;28:327–35.
pubmed: 16574280 doi: 10.1016/j.neurobiolaging.2006.02.007
Arendt T, Brückner MK, Morawski M, et al. Early neurone loss in Alzheimer’s disease: cortical or subcortical? Acta Neuropathol Commun. 2015;3:10.
pubmed: 25853173 pmcid: 4359478 doi: 10.1186/s40478-015-0187-1
Kelly SC, He B, Perez SE, et al. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease. Acta Neuropathol Commun. 2017;5:8.
pubmed: 28109312 pmcid: 5251221 doi: 10.1186/s40478-017-0411-2
Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;2:1403.
pubmed: 63862 doi: 10.1016/S0140-6736(76)91936-X
Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10:122–6.
pubmed: 7283399 doi: 10.1002/ana.410100203
Hall AM, Moore RY, Lopez OL, et al. Basal forebrain atrophy is a presymptomatic marker for Alzheimer’s disease. Alzheimers Dement. 2008;4:271–9.
pubmed: 18631978 doi: 10.1016/j.jalz.2008.04.005
Grothe M, Zaborszky L, Atienza M, et al. Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer’s disease. Cereb Cortex. 2010;20:1685–95.
pubmed: 19889714 doi: 10.1093/cercor/bhp232
Mesulam M, Shaw P, Mash D, et al. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol. 2004;55:815–28.
pubmed: 15174015 doi: 10.1002/ana.20100
Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain. 2015;138(Pt 10):2814–33.
pubmed: 26283673 doi: 10.1093/brain/awv236
Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960–9.
pubmed: 22002422 doi: 10.1097/NEN.0b013e318232a379
Braak H, Del Tredici K. Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 2011;121:589–95.
pubmed: 21516512 doi: 10.1007/s00401-011-0825-z
Braak H, Del Tredici K. Where, when, and in what form does sporadic Alzheimer’s disease begin? Curr Opin Neurol. 2012;25:708–14.
pubmed: 23160422 doi: 10.1097/WCO.0b013e32835a3432
Weinshenker D. Long Road to ruin: noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci. 2018;41(4):211–23.
pubmed: 29475564 pmcid: 5878728 doi: 10.1016/j.tins.2018.01.010
Betts MJ, Kirilina E, Otaduy MCG, et al. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain. 2019;142(9):2558–71.
pubmed: 31327002 pmcid: 6736046 doi: 10.1093/brain/awz193
Teipel SJ, Flatz WH, Heinsen H, et al. Measurement of basal forebrain atrophy in Alzheimer’s disease using MRI. Brain. 2005;128:2626–44.
pubmed: 16014654 doi: 10.1093/brain/awh589
Zaborszky L, Hoemke L, Mohlberg H, et al. Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. NeuroImage. 2008;42:1127–41.
pubmed: 18585468 doi: 10.1016/j.neuroimage.2008.05.055
Grothe MJ, Schuster C, Bauer F, et al. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer’s disease dementia. J Neurol. 2014;261:1939–48.
pubmed: 25059393 doi: 10.1007/s00415-014-7439-z
Grothe M, Heinsen H, Teipel SJ. Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer’s disease. Biol Psychiatry. 2012;71:805–13.
pubmed: 21816388 doi: 10.1016/j.biopsych.2011.06.019
Teipel SJ, Meindl T, Grinberg L, et al. The cholinergic system in mild cognitive impairment and Alzheimer’s disease: an in vivo MRI and DTI study. Hum Brain Mapp. 2011;32:1349–62.
pubmed: 20672311 doi: 10.1002/hbm.21111
Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503–27.
pubmed: 31039256 pmcid: 6536849 doi: 10.1093/brain/awz099
Nelson PT, Lee EB, Cykowski MD, et al. LATE-NC staging in routine neuropathologic diagnosis: an update. Acta Neuropathol. 2023;145(2):159–73.
pubmed: 36512061 doi: 10.1007/s00401-022-02524-2
Nag S, Schneider JA. Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases. Nat Rev Neurol. 2023;19(9):525–41.
pubmed: 37563264 pmcid: 10964248 doi: 10.1038/s41582-023-00846-7
Teipel SJ, Grothe MJ, Alzheimer’s Disease Neuroimaging Initiative. Antemortem basal forebrain atrophy in pure limbic TAR DNA-binding protein 43 pathology compared with pure Alzheimer pathology. Eur J Neurol. 2022;29:1394–401.
pubmed: 35122358 doi: 10.1111/ene.15270
Teipel S, Grothe MJ, Alzheimer’s Disease Neuroimaging Initiative. MRI-based basal forebrain atrophy and volumetric signatures associated with limbic TDP-43 compared to Alzheimer’s disease pathology. Neurobiol Dis. 2023;180:106070.
pubmed: 36898615 doi: 10.1016/j.nbd.2023.106070
Ohm DT, Peterson C, Lobrovich R, et al. Degeneration of the locus coeruleus is a common feature of tauopathies and distinct from TDP-43 proteinopathies in the frontotemporal lobar degeneration spectrum. Acta Neuropathol. 2020;140:675–93.
pubmed: 32804255 pmcid: 7554264 doi: 10.1007/s00401-020-02210-1
Matti N, Javanshiri K, Haglund M, Saenz-Sardá X, Englund E. Locus Coeruleus Degeneration differs between Frontotemporal Lobar Degeneration subtypes. J Alzheimers Dis. 2022;89(2):463–71.
pubmed: 35871340 pmcid: 9535600 doi: 10.3233/JAD-220276
Convery RS, Neason MR, Cash DM, et al. Basal forebrain atrophy in frontotemporal dementia. Neuroimage Clin. 2020;26:102210.
pubmed: 32143137 pmcid: 7058403 doi: 10.1016/j.nicl.2020.102210
Lagarde J, Olivieri P, Tonietto M, et al. Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type. Transl Psychiatry. 2021;11(1):498.
pubmed: 34588422 pmcid: 8481505 doi: 10.1038/s41398-021-01628-9
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–77.
pubmed: 21810890 pmcid: 3170532 doi: 10.1093/brain/awr179
Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–14.
pubmed: 21325651 pmcid: 3059138 doi: 10.1212/WNL.0b013e31821103e6
Lagarde J, Olivieri P, Tonietto M, et al. Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2022;93(5):459–67.
pubmed: 35228270 doi: 10.1136/jnnp-2021-328623
García-Lorenzo D, Longo-Dos Santos C, Ewenczyk C, et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson’s disease. Brain. 2013;136:2120–9.
pubmed: 23801736 pmcid: 3692035 doi: 10.1093/brain/awt152
Shibata E, Sasaki M, Tohyama K, et al. Age-related changes in locus ceruleus on neuromelanin magnetic resonance imaging at 3 Tesla. Magn Reson Med Sci. 2006;5:197–200.
pubmed: 17332710 doi: 10.2463/mrms.5.197
Olivieri P, Lagarde J, Lehericy S, et al. Early alteration of the locus coeruleus in phenotypic variants of Alzheimer’s disease. Ann Clin Transl Neurol. 2019;6:1345–51.
pubmed: 31353860 pmcid: 6649639 doi: 10.1002/acn3.50818
Tustison NJ, Avants BB, Cook PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging. 2010;29:1310–20.
pubmed: 20378467 pmcid: 3071855 doi: 10.1109/TMI.2010.2046908
Manjón JV, Coupé P, volBrain. An online MRI brain Volumetry System. Front Neuroinform. 2016;10:30.
pubmed: 27512372 pmcid: 4961698 doi: 10.3389/fninf.2016.00030
Eickhoff SB, Stephan KE, Mohlberg H, et al. A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. NeuroImage. 2005;25:1325–35.
pubmed: 15850749 doi: 10.1016/j.neuroimage.2004.12.034
Jack CR Jr, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement. 2017;13(3):205–16.
pubmed: 27697430 doi: 10.1016/j.jalz.2016.08.005
Ossenkoppele R, Lyoo CH, Sudre CH, et al. Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease. Alzheimers Dement. 2020;16(2):335–44.
pubmed: 31672482 doi: 10.1016/j.jalz.2019.08.201
Geula C, Dunlop SR, Ayala I, et al. Basal forebrain cholinergic system in the dementias: vulnerability, resilience, and resistance. J Neurochem. 2021;158(6):1394–411.
pubmed: 34272732 pmcid: 8458251 doi: 10.1111/jnc.15471
Kilimann I, Grothe M, Heinsen H, et al. Subregional basal forebrain atrophy in Alzheimer’s disease: a multicenter study. J Alzheimers Dis. 2014;40:687–700.
pubmed: 24503619 pmcid: 4120953 doi: 10.3233/JAD-132345
Galgani A, Giorgi FS. Exploring the role of Locus Coeruleus in Alzheimer’s Disease: a Comprehensive Update on MRI studies and implications. Curr Neurol Neurosci Rep. 2023;23(12):925–36.
pubmed: 38064152 pmcid: 10724305 doi: 10.1007/s11910-023-01324-9
Jacobs HIL, Becker JA, Kwong K, et al. In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer’s disease pathology and cognitive decline. Sci Transl Med. 2021;13(612):eabj2511.
pubmed: 34550726 pmcid: 8641759 doi: 10.1126/scitranslmed.abj2511
Fernández-Cabello S, Kronbichler M, Van Dijk KRA, et al. Basal forebrain volume reliably predicts the cortical spread of Alzheimer’s degeneration. Brain. 2020;143(3):993–1009.
pubmed: 32203580 pmcid: 7092749 doi: 10.1093/brain/awaa012
Galgani A, Lombardo F, Martini N, et al. Magnetic resonance imaging Locus Coeruleus abnormality in amnestic mild cognitive impairment is associated with future progression to dementia. Eur J Neurol. 2023;30(1):32–46.
pubmed: 36086917 doi: 10.1111/ene.15556
Cykowski MD, Takei H, Van Eldik LJ, et al. Hippocampal sclerosis but not normal aging or Alzheimer Disease is Associated with TDP-43 Pathology in the basal forebrain of aged persons. J Neuropathol Exp Neurol. 2016;75:397–407.
pubmed: 26971127 pmcid: 5009476 doi: 10.1093/jnen/nlw014
Quattrini G, Pini L, Boscolo Galazzo I, et al. Microstructural alterations in the locus coeruleus-entorhinal cortex pathway in Alzheimer’s disease and frontotemporal dementia. Alzheimers Dement (Amst). 2024;16(1):e12513.
pubmed: 38213948 doi: 10.1002/dad2.12513
Grothe MJ, Heinsen H, Amaro E Jr, et al. Cognitive correlates of basal forebrain atrophy and Associated cortical hypometabolism in mild cognitive impairment. Cereb Cortex. 2016;26(6):2411–26.
pubmed: 25840425 doi: 10.1093/cercor/bhv062
Cantero JL, Zaborszky L, Atienza M. Volume loss of the Nucleus Basalis of Meynert is Associated with atrophy of innervated regions in mild cognitive impairment. Cereb Cortex. 2017;27(8):3881–9.
pubmed: 27371762
Liu AK, Chang RC, Pearce RK, et al. Nucleus basalis of meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease. Acta Neuropathol. 2015;129(4):527–40.
pubmed: 25633602 pmcid: 4366544 doi: 10.1007/s00401-015-1392-5
Li S. The β-adrenergic hypothesis of synaptic and microglial impairment in Alzheimer’s disease. J Neurochem. 2023;165(3):289–302.
pubmed: 36799441 doi: 10.1111/jnc.15782
Malatt C, Tagliati M. The role of the locus coeruleus/norepinephrine system in the pathogenesis of neurodegenerative disorders: an update. Curr Opin Neurol. 2022;35(2):220–9.
pubmed: 35175974 doi: 10.1097/WCO.0000000000001042
Gamage R, Wagnon I, Rossetti I, et al. Cholinergic modulation of glial function during aging and chronic neuroinflammation. Front Cell Neurosci. 2020;14:577912.
pubmed: 33192323 pmcid: 7594524 doi: 10.3389/fncel.2020.577912
Sibahi A, Gandhi R, Al-Haddad R, et al. Characterization of an automated method to segment the human locus coeruleus. Hum Brain Mapp. 2023;44(9):3913–25.
pubmed: 37126580 pmcid: 10203805 doi: 10.1002/hbm.26324
Mercan D, Heneka MT. The contribution of the Locus Coeruleus-Noradrenaline System Degeneration during the progression of Alzheimer’s Disease. Biology (Basel). 2022;11(12):1822.
pubmed: 36552331
Slater C, Liu Y, Weiss E, et al. The Neuromodulatory Role of the noradrenergic and Cholinergic Systems and their interplay in cognitive functions: a focused review. Brain Sci. 2022;12(7):890.
pubmed: 35884697 pmcid: 9320657 doi: 10.3390/brainsci12070890

Auteurs

Julien Lagarde (J)

Department of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France. j.lagarde@ghu-paris.fr.
Université Paris-Saclay, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, BioMaps, Orsay, F- 91401, France. j.lagarde@ghu-paris.fr.
Université Paris-Cité, Paris, France. j.lagarde@ghu-paris.fr.

Pauline Olivieri (P)

Department of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France.

Matteo Tonietto (M)

Université Paris-Saclay, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, BioMaps, Orsay, F- 91401, France.

Camille Noiray (C)

Department of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France.

Stéphane Lehericy (S)

Centre de NeuroImagerie de Recherche - CENIR, Institut du Cerveau et de la Moelle épinière - ICM, Paris, F-75013, France.
Sorbonne Université, UPMC Univ Paris 06, UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM, Paris, F-75013, France.

Romain Valabrègue (R)

Centre de NeuroImagerie de Recherche - CENIR, Institut du Cerveau et de la Moelle épinière - ICM, Paris, F-75013, France.
Sorbonne Université, UPMC Univ Paris 06, UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM, Paris, F-75013, France.

Fabien Caillé (F)

Université Paris-Saclay, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, BioMaps, Orsay, F- 91401, France.

Philippe Gervais (P)

Université Paris-Saclay, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, BioMaps, Orsay, F- 91401, France.

Martin Moussion (M)

Centre d'Evaluation Troubles Psychiques et Vieillissement, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, Paris, F-75014, France.

Michel Bottlaender (M)

Université Paris-Saclay, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, BioMaps, Orsay, F- 91401, France.
UNIACT, Neurospin, Gif-sur-Yvette, CEA, F-91191, France.

Marie Sarazin (M)

Department of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France.
Université Paris-Saclay, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, BioMaps, Orsay, F- 91401, France.
Université Paris-Cité, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH